Psychedelic Clinical Trials
Find clinical trials studying psilocybin, MDMA, ketamine and other psychedelics. Many trials are actively recruiting participants who haven't found relief from conventional treatments.
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Definium Therapeutics US, Inc.
Evaluation of Ketamine/Midazolam Sedation vs. Fentanyl/Midazolam Sedation for Image-Guided Percutaneous Procedures in Interventional Radiology
CAMC Health System
Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism
Healing Advocacy Fund
Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression
Stanford University
Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia
University Hospital, Montpellier
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Icahn School of Medicine at Mount Sinai
MDMA-Assisted Therapy for Pathological Narcissism
University of Washington
Psilocybin for Treatment-Resistant Depression
University of Colorado, Denver
A Study of Psilocybin for PTSD
Johns Hopkins University
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
Cybin IRL Limited
Psilocybin for Major Depressive Disorder (MDD)
Usona Institute
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder
Peggy C Nopoulos
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
TRYP Therapeutics
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
Centre for Addiction and Mental Health
LSD Occupancy of the Serotonin 2A Receptor in the Human Brain
Rigshospitalet, Denmark
Neural and Physiological Correlates of Psychedelic Sub-states
Robin Carhart-Harris, PhD, MA
Effects of Repeated Psilocybin Dosing in OCD
Yale University
Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
Novartis Pharmaceuticals
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
New York State Psychiatric Institute
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
University of Wisconsin, Madison
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
COMPASS Pathways
Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study
Anders Fink-Jensen, MD, DMSci
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
COMPASS Pathways
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
COMPASS Pathways
Single and Repeat Doses of DMT in Healthy Subjects
Algernon Pharmaceuticals
Ketamine for Multiple Sclerosis Fatigue
Johns Hopkins University
Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder
Ohio State University
Effects of Psilocybin in Obsessive Compulsive Disorder
Johns Hopkins University
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
Eleusis Therapeutics
Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
University of California, San Francisco
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
Ohio State University
Ketamine and Kidney Injury in Cardiac Surgery
Mayo Clinic
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
Covid-19 Vaccine Immune Response in Multiple Sclerosis
University Hospitals of North Midlands NHS Trust
Psilocybin Therapy for Depression in Bipolar II Disorder
University of California, San Francisco
Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain
NYU Langone Health
Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure
Stanford University
Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin
King's College London
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
Johns Hopkins University
Ketamine vs Lidocaine in Traumatic Rib Fractures
Brittany Hoyte
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Bristol-Myers Squibb
Ketamine + Cognitive Training for Suicidality in the Medical Setting
Rebecca Price
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Sheppard Pratt Health System
Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
Keith Heinzerling
Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia
Wilderman Medical Clinic
Browse by Condition
View all conditions →How to Join a Clinical Trial
Clinical trials are research studies that test new treatments. Participating can give you access to cutting-edge therapies while contributing to medical science. Each trial has specific eligibility criteria based on the research goals.
1. Review
Read the trial details, eligibility criteria, and what participation involves.
2. Contact
Reach out to the study team using the contact information provided.
3. Screen
Complete the screening process to determine if you're eligible.